

RECEIVED
CENTRAL FAX CENTER

AUG 18 2004

Attorney Docket No. 6197.214-US
Kanstrup et al.
Serial No. 10/621,302 Filed July 17, 2003
Via Fax No.: 703-872-9306

Attorney Docket No.: 6197.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In re Application of: Kanstrup et al.

Application No.: 10/621,302

Group Art Unit: 1624

Filed: July 17, 2003

Examiner: Berch, Mark L.

Confirmation No.: 2223

For: Heterocyclic Compounds That Are Inhibitors of the Enzyme DPP-IV

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the non-final Office Action on the merits mailed February 18, 2004, having a shortened period for reply of three (3) months, due to expire May 18, 2004, be extended for a period of three (3) months from May 18, 2004, to August 18, 2004, to permit timely filing of the Amendment/Response enclosed herewith.

In the event that an additional extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Attorney Docket No. 6197.214-US
Kanstrup et al.
Serial No. 10/621,302 Filed July 17, 2003
Via Fax No.: 703-872-9306

Please charge the required fee, estimated to be \$950, with this petition and credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 18, 2004



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

AUG 18 2004

Attorney Docket No. 6197.214-US
Kanstrup et al.
Serial No. 10/621,302 Filed July 17, 2003
Via Fax No.: 703-872-9306

Attorney Docket No.: 6197.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In re Application of: Kanstrup et al.

Application No.: 10/621,302

Group Art Unit: 1624

Filed: July 17, 2003

Examiner: Berch, Mark L.

Confirmation No.: 2223

For: Heterocyclic Compounds That Are Inhibitors of the Enzyme DPP-IV

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the non-final Office Action on the merits mailed February 18, 2004, having a shortened period for reply of three (3) months, due to expire May 18, 2004, be extended for a period of three (3) months from May 18, 2004, to August 18, 2004, to permit timely filing of the Amendment/Response enclosed herewith.


In the event that an additional extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Attorney Docket No. 6197.214-US
Kanstrup et al.
Serial No. 10/621,302 Filed July 17, 2003
Via Fax No.: 703-872-9306

Please charge the required fee, estimated to be \$950, with this petition and credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 18, 2004



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE